National Institute of Pharmaceutical Education and Research (Niper), Ahmedabad claims to have developed new class of compounds for treatment of Type-II diabetes and also perfected the manufacturing process for it.
While talking to the media the director of the Institute claimed, “the chemical molecules developed by our institute is different from other drugs available in the market. The institute, has filed application seeking patent for it. The new drug was more efficient and cost effective than other drugs for diabetes available currently in the global market”.
Present anti-diabetic drugs cost between Rs 100 to Rs 650 per mg. But the one developed by Niper costs only Rs 20 per mg and will benefit millions of diabetes patients in the country.
While commenting on the subject a senior diabetologist said: "Reducing the cost of therapy will be a boon. In India, nearly 60% of patients have to mortgage their property to keep their blood sugar under control. If we can predict future complications, it can reduce the financial burden on millions of patients."
Right now Niper conducts MS(Pharma) and doctoral courses. A total of 284 students have passed out from the institute and 92 are currently studying for different postgraduate courses. The institute also offer Ph.D Courses and a total of 15 students have enrolled for PhD programmes.
Niper is among seven national institutes set up in 2007 by the central government for postgraduate teaching and research in pharma.
The institutes building is under construction at a 90 acres of land at an estimated cost of Rs. 497 crores in Chiloda village, adjacent to Indian Institute of Technology (IIT), in Gandhinagar.